Covered recipient · General Payments record
JENNIFER CARDENAS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$1,015.99
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $584.10 | 16 |
| Education | $84.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $335.32 | 6 |
| Incyte Corporation | $135.83 | 3 |
| GlaxoSmithKline, LLC. | $80.40 | 3 |
| Acerta Pharma LLC | $54.04 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.46 | 1 |
| Celgene Corporation | $23.32 | 1 |
| GENZYME CORPORATION | $16.72 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.41 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877461 | CMS |
| ABBVIE INC. | $18.95 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877463 | CMS |
| ABBVIE INC. | $14.63 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877465 | CMS |
| ABBVIE INC. | $144.99 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877467 | CMS |
| ABBVIE INC. | $17.65 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877469 | CMS |
| ABBVIE INC. | $117.69 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106877471 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.53 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104521294 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.51 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104510204 | CMS |
| Celgene Corporation | $23.32 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101172462 | CMS |
| GENZYME CORPORATION | $16.72 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139988789 | CMS |
| GlaxoSmithKline, LLC. | $27.55 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116618011 | CMS |
| GlaxoSmithKline, LLC. | $21.84 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116132599 | CMS |
| GlaxoSmithKline, LLC. | $31.01 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116266069 | CMS |
| Incyte Corporation | $25.87 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141298963 | CMS |
| Incyte Corporation | $24.97 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141223684 | CMS |
| Incyte Corporation | $84.99 | 04/22/2024 | Education | Undisputed | 01/23/2026 | 1141270958 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.46 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144973034 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.